[1] DE SIMEIS D, SERRA S. Actinomycetes: A never-ending source of bioactive compounds—an overview on antibiotics production[J]. Antibiotics (Basel), 2021, 10(5): 483. doi:  10.3390/antibiotics10050483
[2] KOHANSKI M A, DWYER D J, COLLINS J. How antibiotics kill bacteria: from targets to networks[J]. Nature Reviews Microbiology, 2010, 8(6): 423 − 435. doi:  10.1038/nrmicro2333
[3] SERWECIŃSKA L. Antimicrobials and antibiotic-resistant bacteria: A risk to the environment and to public health[J]. Water, 2020, 12(12): 3313. doi:  10.3390/w12123313
[4] NEWMAN D J. Old and modern antibiotic structures with potential for today's infections[J]. Admet and Dmpk, 2022, 10(2): 131 − 146. doi:  10.5599/admet.1272
[5] WILLYARD C. Drug-resistant bacteria ranked[J]. Nature, 2017, 543(7643): 15. doi:  10.1038/nature.2017.21550
[6] SUMBANA J J. Phenotypic and molecular characterization of extraintestinal pathogenic Escherichia coli and other Gram-negative invasive bacteria in Mozambique (Doctoral dissertation, University of Sassari) [D]; University of Sassari, 2020.
[7] SAROWSKA J, FUTOMA-KOLOCH B, JAMA-KMIECIK A, et al. Virulence factors, prevalence and potential transmission of extraintestinal pathogenic Escherichia coli isolated from different sources: recent reports[J]. Gut pathogens, 2019, 11(2): 1 − 16.
[8] KAPER J B, NATARO J P, MOBLEY H L. Pathogenic Escherichia coli[J]. Nature Reviews Microbiology, 2004, 2(2): 123 − 140. doi:  10.1038/nrmicro818
[9] SMITH J, FRATAMICO P. Escherichia coli as a Pathogen [M]. Foodborne diseases.; Elsevier. 2017: 189-208.
[10] PAITAN Y. Current trends in antimicrobial resistance of Escherichia coli [J]. Current Topics in Microbiology and Immunology, 2018, : 181−211.
[11] BEYER P, PAULIN S. The antibacterial research and development pipeline needs urgent solutions[J]. ACS Infectious Diseases, 2020, 6(6): 1289 − 1291. doi:  10.1021/acsinfecdis.0c00044
[12] MILLANAO A R, MORA A Y, VILLAGRA N A, et al. Biological effects of quinolones: a family of broad-spectrum antimicrobial agents[J]. Molecules, 2021, 26(23): 7153. doi:  10.3390/molecules26237153
[13] DU M, ZHANG D, HOU Y, et al. Combined 2D-QSAR, principal component analysis and sensitivity analysis studies on fluoroquinolones’ genotoxicity[J]. International Journal of Environmental Research, 2019, 16(21): 4156.
[14] AL BAHRY S, SIVAKUMAR N, AL-KHAMBASHI M. Effect of nalidixic acid on the morphology and protein expression of Pseudomonas aeruginosa[J]. Asian Pacific Journal of Tropical Medicine, 2012, 5(4): 265 − 269. doi:  10.1016/S1995-7645(12)60037-6
[15] BHATTACHARJEE M K. Antibiotics that inhibit cell wall synthesis [M]. Chemistry of Antibiotics and Related Drugs. ; Springer. 2022: 55-107.
[16] ANDRADE F F, SILVA D, RODRIGUES A, et al. Colistin update on its mechanism of action and resistance, present and future challenges[J]. Microorganisms, 2020, 8(11): 1716. doi:  10.3390/microorganisms8111716
[17] BRAZ V S, MELCHIOR K, MOREIRA C G, et al. Escherichia coli as a multifaceted pathogenic and versatile bacterium[J]. Frontiers in cellular, 2020, 10: 548492.
[18] STOCKER M K, SANSON M L, BERNARDES A A, et al. Acid–base sensor based on sol–gel encapsulation of bromothymol blue in silica: Application for milk spoilage detection[J]. Journal of Sol-Gel Science, 2021, 98: 568 − 579. doi:  10.1007/s10971-021-05529-7
[19] WEINSTEIN M P, LEWIS J S. The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing: Background, Organization, Functions, and Processes[J]. Journal of Clinical Microbiology, 2020, 58(3): e01864 − 01819.
[20] SIMON N, BOCHMAN M L, SEGUIN S, et al. Ciprofloxacin is an inhibitor of the Mcm2-7 replicative helicase[J]. Bioscience Reports, 2013, 33(5): e00072. doi:  10.1042/BSR20130083
[21] HANGAS A, AASUMETS K, KEKäLäINEN N J, et al. Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2[J]. Nucleic Acids Research, 2018, 46(18): 9625 − 9636. doi:  10.1093/nar/gky793
[22] O'SULLIVAN D, HINDS J, BUTCHER P, et al. Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin[J]. Journal of Antimicrobial Chemotherapy, 2008, 62(6): 1199 − 1202. doi:  10.1093/jac/dkn387
[23] AHMED M, KELLEY S O. Enhancing the potency of nalidixic acid toward a bacterial DNA gyrase with conjugated peptides[J]. ACS Chemical Biology, 2017, 12(10): 2563 − 2569. doi:  10.1021/acschembio.7b00540
[24] THOPPIL A A, SHARMA R, KISHORE N. Complexation of β-lactam antibiotic drug carbenicillin to bovine serum albumin: Energetics and conformational studies[J]. Biopolymers: Original Research on Biomolecules, 2008, 89(10): 831 − 840.
[25] LIMA L M, DA SILVA B N M, BARBOSA G, et al. β-lactam antibiotics: An overview from a medicinal chemistry perspective[J]. European Journal of Medicinal Chemistry, 2020, 208: 112829. doi:  10.1016/j.ejmech.2020.112829
[26] JACOBY G A, STRAHILEVITZ J, HOOPER D C, et al. Plasmid-mediated quinolone resistance[J]. Plasmids: Biology, 2015, 2(2): 475 − 503.